Literature DB >> 10456926

Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.

R B Parad1, C J Gerard, D Zurakowski, D P Nichols, G B Pier.   

Abstract

Whether allelic variants of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) independently contribute to pulmonary outcome in CF patients has not been resolved. We used both cross-sectional and mixed-model longitudinal analyses of data from CF patients that were at least 12 years old to determine the influence on pulmonary function (percent predicted forced expiratory volume [FEV(1)]) of the CFTR gene genotype, gender, mucoid Pseudomonas aeruginosa (MPA) infection status, presence of total opsonic antibody to MPA, and, separately, the opsonic antibody activity specific to the mucoid exopolysaccharide (MEP) surface antigen. Two different factors were independently associated with the lack of MPA infection: a high level of MEP-specific opsonic activity (MSOA), implicating an immunologically based mechanism of resistance to infection, and a lack of any type of opsonic antibody to MPA, indicative of no significant exposure or infection. This latter phenotype was found in a subset of CF patients who carried at least one uncommon CFTR gene allele suggestive of a genetic basis for resistance to infection in this group of older CF patients. For CF patients in whom both CFTR gene alleles were identified by screening for the 12 most common variants (75% of alleles), cross-sectional analysis showed that MPA infection was best correlated with lower percent predicted FEV(1), while genotype (two versus one DeltaF508 CFTR gene allele) and a low level of MSOA were associated with increased risk of infection. A mixed-model analysis of longitudinal spirometric measurements that considered multiple risk factors to derive regression equations was used to determine which clinical parameters had the greatest effect on the annual rate of decline in percent predicted FEV(1). This analysis showed that the CFTR gene genotype only modestly modified the constant (y intercept) of the derived equations, while gender and MPA infection status had the largest effects on annual rates of decline in percent predicted FEV(1). These results indicate that the CFTR genotype is usually not a primary determinant of pulmonary function in most CF patients, but gender and MPA infection status are. Infection status is potentially influenced by both immunologic (a high level of MSOA) and genetic factors, such as carriage of a CFTR gene allele that leads to a diagnosis of CF but still confers resistance to infection that is comparable to that of the wild-type CFTR gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456926      PMCID: PMC96804     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.

Authors:  E Kerem; M Corey; R Gold; H Levison
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

2.  Identification of the cystic fibrosis gene: genetic analysis.

Authors:  B Kerem; J M Rommens; J A Buchanan; D Markiewicz; T K Cox; A Chakravarti; M Buchwald; L C Tsui
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

3.  Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections.

Authors:  G B Pier; G J Small; H B Warren
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

4.  Unbalanced repeated-measures models with structured covariance matrices.

Authors:  R I Jennrich; M D Schluchter
Journal:  Biometrics       Date:  1986-12       Impact factor: 2.571

5.  Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response.

Authors:  S S Pedersen; A Kharazmi; F Espersen; N Høiby
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Authors:  R J Knudson; M D Lebowitz; C J Holberg; B Burrows
Journal:  Am Rev Respir Dis       Date:  1983-06

7.  Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis.

Authors:  M Corey; L Edwards; H Levison; M Knowles
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

8.  Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.

Authors:  G B Pier; W J Matthews; D D Eardley
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

9.  Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis.

Authors:  G B Pier; J M Saunders; P Ames; M S Edwards; H Auerbach; J Goldfarb; D P Speert; S Hurwitch
Journal:  N Engl J Med       Date:  1987-09-24       Impact factor: 91.245

10.  Linked marker haplotypes and the delta F508 mutation in adults with mild pulmonary disease and cystic fibrosis.

Authors:  G Santis; L Osborne; R A Knight; M E Hodson
Journal:  Lancet       Date:  1990-06-16       Impact factor: 79.321

View more
  49 in total

Review 1.  Cystic fibrosis in adults: current and future management strategies.

Authors:  Brian M Morrissey; Bettina C Schock; Gregory P Marelich; Carroll E Cross
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

2.  Microsphere bead arrays and sequence validation of 5/7/9T genotypes for multiplex screening of cystic fibrosis polymorphisms.

Authors:  Andrew G Hadd; Walairat Laosinchai-Wolf; Chris R Novak; Marty R Badgett; Lesley A Isgur; Marianna Goldrick; Cindy R Walkerpeach
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

3.  Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report.

Authors:  Bonnie W Ramsey; Susan Banks-Schlegel; Frank J Accurso; Richard C Boucher; Garry R Cutting; John F Engelhardt; William B Guggino; Christopher L Karp; Michael R Knowles; Jay K Kolls; John J LiPuma; Susan Lynch; Paul B McCray; Ronald C Rubenstein; Pradeep K Singh; Eric Sorscher; Michael Welsh
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa.

Authors:  Amanda G Oglesby-Sherrouse; Louise Djapgne; Angela T Nguyen; Adriana I Vasil; Michael L Vasil
Journal:  Pathog Dis       Date:  2014-02-10       Impact factor: 3.166

6.  Modulation of cystic fibrosis lung disease by variants in interleukin-8.

Authors:  A D Hillian; D Londono; J M Dunn; K A B Goddard; R G Pace; M R Knowles; M L Drumm
Journal:  Genes Immun       Date:  2008-06-19       Impact factor: 2.676

7.  Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.

Authors:  Xavier Mulet; María D Maciá; Ana Mena; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

8.  Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Authors:  Scott D Sagel; Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Jeffrey S Wagener; Bonnie W Ramsey
Journal:  J Pediatr       Date:  2008-09-25       Impact factor: 4.406

Review 9.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

10.  Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.

Authors:  Nina Reiniger; Martin M Lee; Fadie T Coleman; Christopher Ray; David E Golan; Gerald B Pier
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.